UNLEASHING THE
PRECISION OF ANTIBODIES
AND THE POWER OF RADIOACTIVITY

ABOUT US

Pretargeted Theranostics

PreTT is transforming cancer treatment with advanced pretargeted radioligand therapies that surpass traditional methods. Our proprietary technology enhances radioimmunotherapy, using monoclonal antibodies (mAbs) for precise targeting of cancer cells while sparing healthy tissue. This innovation maximizes radiation’s therapeutic power, off ering a powerful new tool in the fight against cancer.

BACKGROUND

RADIOTHERANOSTICS

Radioligand Therapy (RLT) is a highly effective and more precise way to treat tumours by using targetedradiation. Radioligand Therapy works not only where chemotherapies fail, but also in the treatment of naïve patients.

TECHNOLOGY

Our Innovative Solution

Monoclonal antibodies (mAbs) are one of the most desirable targeting vectors to carry the radiation to tumour cells due to the exquisite specificity. Unfortunately, and in contrast to peptides, mAbs accumulate slowly into cancers and excrete slowly from the rest of the body. This characteristic disqualifies mAbs for almost all RLTs as the initial radiation represents a burden on healthy tissues and limits the dose that can be administered. Our pretargeting platform, which separates the (non-radioactive) mAb accumulation and excretion from the actual radioactivity administration, circumvents this intrinsic radiotoxicity challenge and takes full advantage of their precision.

BEHIND PRETT

Meet The Team

GET IN TOUCH

Contact Us!

 
 
 
 
 

Follow us on LinkedIn 

Get in touch with us for more info